Numan Adds $60M for Expansion, Women’s Health Push

Traditionally focused on men’s health, the U.K.-based telehealth platform reported that its revenue more than doubled to over $90 million last year

Numan, a United Kingdom-based telehealth company offering a range of services including GLP-1s and erectile dysfunction medications, has secured an additional $60 million in funding as it looks to expand its signature men’s health services and push deeper into women’s health.

The funding round was led by Big Pi Ventures and Endeavor Catalyst, who were joined by existing investors White Star Capital and Novator. The round also included $27 million in growth capital from HSBC Innovation Banking UK. 

Numan didn’t disclose details of the rest of the founding round, but it’s been reported that financing included a $30 million equity investment that was an extension of the company’s Series B round.

Founded in 2018, Numan has primarily operated in the men’s health space, offering customers access to GLP-1 weight-loss drugs like Mounjaro and Wegovy, erectile dysfunction (ED) medication, testosterone replacement therapy (TRT), personalized blood testing and supplements. 

The company says it plans to use the new funding to expand its reach across the U.K., improve its men’s health services and introduce a new hormonal offering for women’s health. Numan also plans to build out its AI-powered health coach and expand its team internationally, including in Greece. 

“Numan has evolved significantly over the past 18 months,” the company’s founder and CEO Sokratis Papafloratos wrote in a LinkedIn post announcing the funding news. “We now serve both men and women. Obesity care has become a big part of our platform, and we’ve built a world-class, AI-powered health coach that is already delivering meaningful results. We’ve expanded our men’s health services to treat root causes like testosterone deficiency, and are launching a comprehensive hormonal health proposition for women.”

According to Papafloratos, Numan has treated over 650,000 patients to date, with revenue more than doubling to over $90 million in 2024, its first year of profitability. In 2025, the company says it’s on track to achieve 150% growth. 

As the telehealth space heats up, Numan will compete with platforms such as Hims & Hers in the U.K. market. Last month, the popular San Francisco-based company acquired Zava in a bid to expand its presence across Western Europe.